Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data

Newron Receives Second Tranche from Financing Agreement with European Investment Bank (EIB)

Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome

Newron Initiates Outreach on First Global Rett Syndrome Burden of Illness Survey in Collaboration with the Rett Community

Newron Pharmaceuticals: Commercialization partner Meiji Seika together with Eisai announce the approval of safinamide for Parkinson’s disease in Japan

Newron reports half-year 2019 results

Newron’s commercialization partner Zambon and Valeo Pharma announce the launch of Onstryv® (safinamide) for Parkinson’s disease in Canada

Newron Receives First Tranche from Financing Agreement with European Investment Bank (EIB)

Newron Pharmaceuticals now also listed on the primary market of the Düsseldorf Stock Exchange and on XETRA

Newron Pharmaceuticals to Present at the JMP Securities Life Sciences Conference

Pagination